Log inSign up
AAOIFI No. 21 screening

Is PRLD halal?

Prelude Therapeutics Incorporat

Not halal

Prelude Therapeutics Incorporat did not pass AAOIFI screening. The failed check is shown below.

Checked: 13 October 2026

Exchange

NASDAQ

Price

3.26

Day

-1.81%

Market cap

$297.9M

Industry

Biotechnology

Sector

Healthcare

What the company does

Prelude Therapeutics develops precision cancer drugs — a SMARCA2 degrader (PRT3789) plus CDK4/6 and MCL1 inhibitors — in early clinical trials. No commercial product; funded by investors.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $0 ÷ 36-month average market cap $171.06M = 0.0%

    0.0%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $151.76M ÷ 36-month average market cap $171.06M = 88.7%

    88.7%

    Fail

  • Non-compliant income / total revenue

    limit 5%

    —

    No data

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $297.87M.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyPRLD's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →